Exogenous high-mobility group box 1 improves myocardial recovery after acute global ischemia/reperfusion injury

Aaron M. Abarbanell, Jacob A. Hartley, Jeremy L. Herrmann, Brent R. Weil, Yue Wang, Mariuxi C. Manukyan, Jeffrey A. Poynter, Daniel R. Meldrum

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: High-mobility group box 1 (HMGB1) is a mediator of inflammation with dose-dependent effects. In the setting of regional myocardial infarction, a high-dose HMGB1 treatment decreases myocardial function, whereas low-dose HMGB1 improves function; however, it is unknown what role HMGB1 has in the setting of global ischemia/reperfusion (I/R) injury. We hypothesized that a low-dose HMGB1 treatment would improve myocardial functional recovery and decrease infarct size after global I/R injury in association with increased levels of cardioprotective paracrine factors and decreased inflammation. Methods: Adult rat hearts were isolated and perfused using the Langendorff method and were subjected to global I/R and treatment with either the vehicle, 200-ng HMGB1, or 1-μg HMGB1. The treatment was administered during 1 min at the start of reperfusion, and myocardial function was measured for 60 min of reperfusion. At the end of reperfusion, the hearts were sectioned and incubated in triphenyltetrazolium chloride to assess myocardial infarct size or homogenized to measure levels of inflammatory cytokines and growth factors. Results: Postischemic treatment with 200-ng HMGB1 significantly improved myocardial functional recovery after global I/R in association with decreased infarct size and decreased interleukin-1 (IL-1), IL-6, IL-10, and vascular endothelial growth factor (VEGF) levels. In addition, 1-μg HMGB1 decreased myocardial inflammation but did not result in subsequent improvement in functional recovery. Conclusion: In the setting of global I/R, 200-ng postischemic HMGB1 treatment improves myocardial function and decreases infarct size in association with suppressed myocardial inflammation. These results suggest a potential role for exogenous HMGB1therapy in the acute postischemic period.

Original languageEnglish (US)
Pages (from-to)329-335
Number of pages7
JournalSurgery
Volume149
Issue number3
DOIs
StatePublished - Mar 2011
Externally publishedYes

Fingerprint

Reperfusion Injury
Reperfusion
Ischemia
Inflammation
Myocardial Infarction
Inflammation Mediators
Myocardial Reperfusion
Interleukin-1
Interleukin-10
Vascular Endothelial Growth Factor A
Interleukin-6
Intercellular Signaling Peptides and Proteins
Cytokines

ASJC Scopus subject areas

  • Surgery

Cite this

Abarbanell, A. M., Hartley, J. A., Herrmann, J. L., Weil, B. R., Wang, Y., Manukyan, M. C., ... Meldrum, D. R. (2011). Exogenous high-mobility group box 1 improves myocardial recovery after acute global ischemia/reperfusion injury. Surgery, 149(3), 329-335. https://doi.org/10.1016/j.surg.2010.07.002

Exogenous high-mobility group box 1 improves myocardial recovery after acute global ischemia/reperfusion injury. / Abarbanell, Aaron M.; Hartley, Jacob A.; Herrmann, Jeremy L.; Weil, Brent R.; Wang, Yue; Manukyan, Mariuxi C.; Poynter, Jeffrey A.; Meldrum, Daniel R.

In: Surgery, Vol. 149, No. 3, 03.2011, p. 329-335.

Research output: Contribution to journalArticle

Abarbanell, AM, Hartley, JA, Herrmann, JL, Weil, BR, Wang, Y, Manukyan, MC, Poynter, JA & Meldrum, DR 2011, 'Exogenous high-mobility group box 1 improves myocardial recovery after acute global ischemia/reperfusion injury', Surgery, vol. 149, no. 3, pp. 329-335. https://doi.org/10.1016/j.surg.2010.07.002
Abarbanell, Aaron M. ; Hartley, Jacob A. ; Herrmann, Jeremy L. ; Weil, Brent R. ; Wang, Yue ; Manukyan, Mariuxi C. ; Poynter, Jeffrey A. ; Meldrum, Daniel R. / Exogenous high-mobility group box 1 improves myocardial recovery after acute global ischemia/reperfusion injury. In: Surgery. 2011 ; Vol. 149, No. 3. pp. 329-335.
@article{c3a97cb3fe4e4a67b2b8486d5865bff1,
title = "Exogenous high-mobility group box 1 improves myocardial recovery after acute global ischemia/reperfusion injury",
abstract = "Background: High-mobility group box 1 (HMGB1) is a mediator of inflammation with dose-dependent effects. In the setting of regional myocardial infarction, a high-dose HMGB1 treatment decreases myocardial function, whereas low-dose HMGB1 improves function; however, it is unknown what role HMGB1 has in the setting of global ischemia/reperfusion (I/R) injury. We hypothesized that a low-dose HMGB1 treatment would improve myocardial functional recovery and decrease infarct size after global I/R injury in association with increased levels of cardioprotective paracrine factors and decreased inflammation. Methods: Adult rat hearts were isolated and perfused using the Langendorff method and were subjected to global I/R and treatment with either the vehicle, 200-ng HMGB1, or 1-μg HMGB1. The treatment was administered during 1 min at the start of reperfusion, and myocardial function was measured for 60 min of reperfusion. At the end of reperfusion, the hearts were sectioned and incubated in triphenyltetrazolium chloride to assess myocardial infarct size or homogenized to measure levels of inflammatory cytokines and growth factors. Results: Postischemic treatment with 200-ng HMGB1 significantly improved myocardial functional recovery after global I/R in association with decreased infarct size and decreased interleukin-1 (IL-1), IL-6, IL-10, and vascular endothelial growth factor (VEGF) levels. In addition, 1-μg HMGB1 decreased myocardial inflammation but did not result in subsequent improvement in functional recovery. Conclusion: In the setting of global I/R, 200-ng postischemic HMGB1 treatment improves myocardial function and decreases infarct size in association with suppressed myocardial inflammation. These results suggest a potential role for exogenous HMGB1therapy in the acute postischemic period.",
author = "Abarbanell, {Aaron M.} and Hartley, {Jacob A.} and Herrmann, {Jeremy L.} and Weil, {Brent R.} and Yue Wang and Manukyan, {Mariuxi C.} and Poynter, {Jeffrey A.} and Meldrum, {Daniel R.}",
year = "2011",
month = "3",
doi = "10.1016/j.surg.2010.07.002",
language = "English (US)",
volume = "149",
pages = "329--335",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Exogenous high-mobility group box 1 improves myocardial recovery after acute global ischemia/reperfusion injury

AU - Abarbanell, Aaron M.

AU - Hartley, Jacob A.

AU - Herrmann, Jeremy L.

AU - Weil, Brent R.

AU - Wang, Yue

AU - Manukyan, Mariuxi C.

AU - Poynter, Jeffrey A.

AU - Meldrum, Daniel R.

PY - 2011/3

Y1 - 2011/3

N2 - Background: High-mobility group box 1 (HMGB1) is a mediator of inflammation with dose-dependent effects. In the setting of regional myocardial infarction, a high-dose HMGB1 treatment decreases myocardial function, whereas low-dose HMGB1 improves function; however, it is unknown what role HMGB1 has in the setting of global ischemia/reperfusion (I/R) injury. We hypothesized that a low-dose HMGB1 treatment would improve myocardial functional recovery and decrease infarct size after global I/R injury in association with increased levels of cardioprotective paracrine factors and decreased inflammation. Methods: Adult rat hearts were isolated and perfused using the Langendorff method and were subjected to global I/R and treatment with either the vehicle, 200-ng HMGB1, or 1-μg HMGB1. The treatment was administered during 1 min at the start of reperfusion, and myocardial function was measured for 60 min of reperfusion. At the end of reperfusion, the hearts were sectioned and incubated in triphenyltetrazolium chloride to assess myocardial infarct size or homogenized to measure levels of inflammatory cytokines and growth factors. Results: Postischemic treatment with 200-ng HMGB1 significantly improved myocardial functional recovery after global I/R in association with decreased infarct size and decreased interleukin-1 (IL-1), IL-6, IL-10, and vascular endothelial growth factor (VEGF) levels. In addition, 1-μg HMGB1 decreased myocardial inflammation but did not result in subsequent improvement in functional recovery. Conclusion: In the setting of global I/R, 200-ng postischemic HMGB1 treatment improves myocardial function and decreases infarct size in association with suppressed myocardial inflammation. These results suggest a potential role for exogenous HMGB1therapy in the acute postischemic period.

AB - Background: High-mobility group box 1 (HMGB1) is a mediator of inflammation with dose-dependent effects. In the setting of regional myocardial infarction, a high-dose HMGB1 treatment decreases myocardial function, whereas low-dose HMGB1 improves function; however, it is unknown what role HMGB1 has in the setting of global ischemia/reperfusion (I/R) injury. We hypothesized that a low-dose HMGB1 treatment would improve myocardial functional recovery and decrease infarct size after global I/R injury in association with increased levels of cardioprotective paracrine factors and decreased inflammation. Methods: Adult rat hearts were isolated and perfused using the Langendorff method and were subjected to global I/R and treatment with either the vehicle, 200-ng HMGB1, or 1-μg HMGB1. The treatment was administered during 1 min at the start of reperfusion, and myocardial function was measured for 60 min of reperfusion. At the end of reperfusion, the hearts were sectioned and incubated in triphenyltetrazolium chloride to assess myocardial infarct size or homogenized to measure levels of inflammatory cytokines and growth factors. Results: Postischemic treatment with 200-ng HMGB1 significantly improved myocardial functional recovery after global I/R in association with decreased infarct size and decreased interleukin-1 (IL-1), IL-6, IL-10, and vascular endothelial growth factor (VEGF) levels. In addition, 1-μg HMGB1 decreased myocardial inflammation but did not result in subsequent improvement in functional recovery. Conclusion: In the setting of global I/R, 200-ng postischemic HMGB1 treatment improves myocardial function and decreases infarct size in association with suppressed myocardial inflammation. These results suggest a potential role for exogenous HMGB1therapy in the acute postischemic period.

UR - http://www.scopus.com/inward/record.url?scp=79951955348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951955348&partnerID=8YFLogxK

U2 - 10.1016/j.surg.2010.07.002

DO - 10.1016/j.surg.2010.07.002

M3 - Article

C2 - 20723957

AN - SCOPUS:79951955348

VL - 149

SP - 329

EP - 335

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 3

ER -